Advertisement
U.S. Markets open in 9 hrs 8 mins
S&P Futures
5,884.25 -2.75 (-0.05%) Dow Futures
43,478.00 -33.00 (-0.08%) Nasdaq Futures
20,364.25 -3.75 (-0.02%) Russell 2000 Futures
2,292.90 -4.80 (-0.21%) Crude Oil
70.88 +0.21 (+0.30%) Gold
2,725.80 +18.30 (+0.68%)
GeneDx Holdings Corp. (WGSWW)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Follow
At close: 04:00PM EDT
| Previous Close | 0.2200 |
| Open | 0.2400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1700 - 0.2400 |
| 52 Week Range | 0.1700 - 0.2400 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
GeneDx Holdings Corp (WGS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...
GeneDx Holdings Corp (WGS) reports a 52% revenue increase and significant margin expansion, while raising full-year guidance despite ongoing challenges.
Business WireGeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
STAMFORD, Conn., October 08, 2024--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for more than 14,000 infants through its participation in groundbreaking research studies which aim to explore the clinical utility and implementation of utilizing genome sequencing to expand standard newborn screening (NBS). Through these studies, GeneDx has conducted more gNBS than any other lab and
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.